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Abstract 27 
Resolution of inflammation is now known to be an active process which in part is 28 
instigated and controlled by specialised pro-resolving lipid mediators (SPM’s) derived 29 
from dietary omega-3 fatty acids. Resolvin E1 (RvE1) is one of these SPM’s derived 30 
from the omega-3 fatty acid eicosapentaenoic acid. Using both molecular and 31 
phenotypic functional measures we report that in a model of Lipopolysaccharide 32 
(LPS) induced inflammation, RvE1 attenuated mRNA gene expression levels of both 33 
interlukin-6 and monocyte chemoattractant protein-1 whilst having no effect on 34 
tumour necrosis factor-α or Interlukin-1β in C2C12 skeletal muscle myotubes. 35 
Findings at the molecular level were transferred into similar changes in extracellular 36 
protein levels of the corresponding genes with the greatest attenuation being noted 37 
in IL-6 protein concentrations. RvE1 instigated beneficial morphological changes 38 
through the prevention of endotoxin induced skeletal muscle atrophy, thus resulting 39 
in a rescue of endotoxin force losses in tissue engineered skeletal muscle. These 40 
findings demonstrate, in our model of endotoxin induced inflammation in skeletal 41 
muscle, that RvE1 has pro-resolving properties in this cell type. Our data provides 42 
rationale for further investigation into the mechanistic action of RvE1 in skeletal 43 
muscle, with the vision of having potential benefits for the prevention/resolution of in-44 
vivo skeletal muscle atrophy. 45 
Introduction 46 
A loss of skeletal muscle size (wasting) is common in a number of disease states as 47 
well as being prevalent  in the ‘healthy’ ageing process (Romanick, Thompson & 48 
Brown-Borg, 2013). In turn skeletal muscle wasting impairs functional capacity, 49 
which is associated with impaired quality of life and increased mortality (Ruiz et al., 50 
2008; Roshanravan et al., 2017). Systemic and local inflammation is often prevalent 51 
in elderly individuals (Argilés et al. 2005) and cachexic diseases (Saini et al., 2006; 52 
Candore et al., 2010) and is therefore thought to play a major role in mediating the 53 
loss of skeletal muscle size. Direct evidence for this has come from in-vitro studies, 54 
where incubation of myotubes with pro-inflammatory cytokines causes atrophy and 55 
up regulation of catabolic signalling pathways (Li et al., 1998; Girven et al., 2016; 56 
Alvarez et al., 2002). There is therefore a need to further develop intervention 57 
strategies aimed at dampening or resolving inflammation in order to prevent skeletal 58 
muscle wasting and offset subsequent decline in muscle function. 59 
Omega-3 polyunsaturated fatty acids (ω-3) are bioactive lipids found in a variety of 60 
foods including fish oils. Nuts and seeds. The most common PUFA’s are 61 
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA), which have shown 62 
to elicit a variety of potential health benefits in both clinical and laboratory based 63 
studies (Chagas et al., 2017; Calder et al., 2017; Poudyal et al., 2011). Though the 64 
beneficial effects of omega-3’s is now widely accepted in specific disease states 65 
such as Cardiovascular disease (Tavazzi et al., 2008), the mechanisms of action are 66 
still poorly described. Research investigated the role of membrane make up both in 67 
terms of lipid raft formation and the ratio of omega-3:omega-6 in the lipid bilayer 68 
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structure (Calder, 2011). Though these factors may contribute to the anti-69 
inflammatory role of omega-3 fatty acids, cellular based research proposed a novel 70 
set of naturally occurring ω-3 derived mediators termed Specialised Pro-Resolving 71 
Mediators (SPM’s) which have been identified as having pro-resolving effects in 72 
several cell types, and may be critical in defining the health benefits of ω-3 (Serhan 73 
et al., 2000; Liu et al., 2017; Norling et al., 2016; Jeromson et al., 2015).  74 
The ‘E-series’ resolvins are biosynthesised from the omega-3 fatty acid 75 
Eicosapentaenoic acid (EPA). In particular 5S,12R,18R-trihydroxy-76 
6Z,8E,10E,14Z,16E-eicosapentaenoic acid (RvE1) is synthesised during the 77 
metabolism of EPA by either acetylated cyclooxygenase-2 (COX-2) or the mono-78 
hydroxylase PY450 (Serhan et al., 2000; Serhan, 2004). Indeed, the detection of 79 
RvE1 at nanogram concentrations has been reported in-vivo (Ohira et al., 2010) and 80 
at these concentrations RvE1 has been shown to elicit pro-resolving actions in-vitro in 81 
an acute inflammatory model of leukocyte infiltration (Schwab et al., 2007). Further 82 
investigations have shown that RvE1 is able to attenuate Lipopolysaccharide (LPS) 83 
induced pro-inflammatory cytokine transcription in pancreatic islets (Lund et al., 84 
2010) and can reduce  circulating levels of Interleukin-1β (IL-1β) and Interleukin-6 85 
(IL-6) in  animal (murine) models (Hasturk et al., 2007; Campbell et al., 2010; Seki et 86 
al., 2010). Importantly, Lund and colleagues found that inflammatory markers such 87 
as Tumour Necrosis Factor-alpha (TNF-α) and Monocyte chemotactic protein 1 88 
(CcL-2) were reduced to the largest extent when RvE1 was co-incubated with LPS 89 
treated human pancreatic islets in vitro, which is of particular interest in skeletal 90 
muscle physiology as both play roles in the initiation and infiltration phases of the 91 
inflammatory process in skeletal muscle (Lund et al., 2010) highlighting the potential 92 
for advantageous properties of RvE1 in the resolution of skeletal muscle 93 
inflammation. Moreover, cyclic production of IL-6 through IL-1β signalling may further 94 
exacerbate atrophy in skeletal muscle (Haddad et al., 2005; Luo et al., 2003), thus 95 
highlighting the importance of attenuating levels of these cytokines. It is therefore 96 
plausible that RvE1 may have efficacy as a therapeutic intervention for the resolution 97 
of inflammatory signalling and prevent subsequent atrophy in skeletal muscle. 98 
The aim of the current study was to investigate the preventative effects of RvE1 on 99 
LPS induced inflammation in C2C12 in-vitro muscle cultures to provide a first 100 
indication of its role skeletal muscle inflammation. Initially we explored the time 101 
course of TNFα, IL-6, IL-1β and CcL-2 induction following incubation of myotubes 102 
with LPS, and thereafter sought to determine if the elevations in pro-inflammatory 103 
cytokine production could be prevented by the addition of RvE1 to the cultures. 104 
Thereafter we investigated if RvE1 could prevent inflammation induced myotube 105 
atrophy and whether this would translate in to improvements in muscle function 106 
utilising ‘3D’-skeletal muscle tissue engineering techniques.  107 
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 108 
Methods 109 
Cell Culture 110 
The C2C12 murine myoblast cell line (C2C12) was used for all experiments. 111 
C2C12’s were cultured at 37°C and 5% CO2 (HeraCell, Thermo Scientific, UK) in 112 
growth medium (GM) composed of: Dulbecco’s modified Eagle’s medium (DMEM) 113 
(Fisher Scientific, UK) plus 20% FBS (PAN Biotech, Germany), and 1% penicillin–114 
streptomycin (PS) solution (Invitrogen, Paisley, UK), until 80-95% confluency was 115 
attained. Cells were then enzymatically dissociated using Trypsin-EDTA (Sigma 116 
Aldrich, UK) and counted using the trypan blue exclusion method and subsequently 117 
seeded into 12 well plates (Thermo-Scientific) at a density of 12.5x10-3 cells/cm2 in 118 
standard GM. Cells were grown to confluency (approximately 3 days), at which point 119 
medium was changed to differentiation media (DM) composed of DMEM (Fisher 120 
Scientific, UK) plus 2% Horse Serum (HS) (Fisher Scientific, UK), and 1% penicillin–121 
streptomycin (PS) solution (Invitrogen, Paisley, UK) to initiate differentiation. 122 
Following three days of differentiation, myotubes were exposed to one of 3 123 
conditions: i) Vehicle Control (CON): DM + 0.1 μl/ml EtOH; ii) LPS (LPS): DM + 100 124 
ng/ml LPS (Sigma Aldrich, UK); iii) Resolvin E1 (RvE1): DM + 100 ng/ml LPS + 100 125 
nM RvE1 (Bertin Pharma, France) and subsequently analysed for mRNA expression, 126 
myotube size and myokine release. Specifically, RNA was extracted at 0.5, 1.5, 3 127 
and 6 h of experimental treatment. Based on the initial mRNA induction, following 3 128 
hours of treatment, medias were removed and replaced with standard DM for a 129 
further 72 h, at which point cells were fixed for immunocytochemistry analysis and 130 
conditioned mediums harvested for further analysis. Furthermore, initial mRNA 131 
screening of the basal effect of RvE1 showed no effect on the genes of interest 132 
(Figure S4), thus authors deemed the condition unnecessary for subsequent 133 
experimentation. 134 
To determine if the inflammatory stimulus could impact on muscle force production 135 
and the effects of RvE1, a tissue engineering approach was employed. Fibrin based 136 
hydrogels were fabricated as previously described (Martin, Aguilar-Agon, et al. 137 
2017). Briefly, two 6mm sutures were pinned into PDMS (Sylgard 184 Elastomer, 138 
Dow Corning, UK) coated 35mm plates 12mm apart using 0.15mm minutien pins 139 
(Entomoravia, Czech Republic). Plates were sterilised using Ultraviolet light and 140 
washing with 70% ethanol and subsequently left to dry for 1 hour. Each plate then 141 
received 500µl of GM containing 10U/ml thrombin (Sigma-Aldrich) and 80µg/ml 142 
aprotinin (Sigma-Aldrich) which was spread evenly over the surface of the plate 143 
ensuring that the sutures were covered. 200µl of 20mg/ml stock fibrinogen (Sigma-144 
Aldrich) solution was then added to the plate, and was agitated gently to ensure 145 
even distribution and then left to incubate for 10 minutes at room temperature before 146 
being transferred to the incubator (37°C) for one hour for polymerisation. Post 147 
incubation, 100,000 C2C12’s seeded on the surface of each hydrogel in GM + 0.25 148 
mg/ml of 6-Aminocaproic acid (AA). Once cells reached confluency (approximately 3 149 
V 
 
days) medium was changed to DM + 0.5 mg/ml AA for 2 days. Post differentiation, 150 
cells were maintained in maintenance medium consisting of DMEM, 7% FBS, 1%PS 151 
and 0.5 mg/ml AA (MM) for the remainder of the 14-day culture period. 72 h before 152 
the end of the 14-day culture period experimental hydrogels were changed into one 153 
of 3 conditions: i) CON; ii) LPS; iii) RvE1 as described above. After 3 h of incubation 154 
in the experimental medias, medias were removed and replaced with MM for the 155 
remainder of the culture period. All experiments were conducted with cells between 156 
passages 4 and 8 (n=9, across 3 biological repeats for each analysis method). 157 
 158 
RNA Extraction 159 
Cells isolated for mRNA analysis were lysed in 400 μl of TRI Reagent and frozen at -160 
80˚C prior to further analysis. RNA extraction was performed as per the 161 
manufacturer’s instructions. In brief, chloroform was added to ensure dissociation of 162 
nucleotide complexes (0.2 ml per 1 ml of TRI reagent), and samples were agitated 163 
and left to stand for 5 mins before being centrifuged at 12,000 g for 15 min. The 164 
aqueous phase was removed and 2-proponal (0.5 ml per 1 ml of TRI reagent) was 165 
added to the aqueous phase and mixed by inversion. Following 10 minutes’ 166 
incubation at room temperature samples were centrifuged at 12,000 g for 10mins to 167 
pellet RNA. RNA pellets were washed in 75% ethanol, centrifuged for a further 5mins 168 
at 7,500 g, and air dried for 5-10 mins. Once isolated, RNA was suspended in 50 μl 169 
RNA storage solution (Ambion, Life Technologies) and stored in RNase free tubes 170 
for mRNA analysis. 171 
 172 
RT-qPCR 173 
One step quantitative RT-qPCR was used to determine expression of target mRNA’s 174 
in C2C12 cultures. Primer sequences (Table 1) were checked for specificity and 175 
assay efficiency by performing standard curve analysis with a top standard of 200 ng 176 
of RNA. Output was analysed using ViiA 7 RUO Software where melt curve analysis 177 
was used to check for specificity of primers. Optimisation of standard curves was 178 
assumed with efficiencies of 100 ± 10%.  179 
Reactions were made up in 384 well RNase free plates (Applied Biosystems, UK) 180 
and consisted of 20 ng (4 ng/µl) of RNA, 0.1 μl of both forward and reverse primers 181 
(Life Technologies) (Table 1), 0.1 μl of Quantifast Reverse Transcriptase kit (Qiagen) 182 
and 4.7 μl of SYBR green mix (Qiagen) to create 10 μl reactions. Once prepared, 183 
plates were transferred to the ViiA 7™ Real Time PCR thermal cycler (Applied 184 
Biosystems, Life Technologies) which was programmed to perform the following 185 
steps: 10 min hold at 50°C (reverse transcription), followed by a 5 min hold at 95 °C 186 
(activation of ‘hot start’ Taq polymerase), and cycling between 95 °C for 10s 187 
(denaturation) and 60 °C for 30 s (annealing and extension). Fluorescence was 188 
detected after every cycle and data was analysed using RPIIβ as the housekeeping 189 
gene. Data was made relative using the comparative Ct method (Livak and 190 
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Schmittgen 2001) with any changes in target genes being in comparison to that of 191 
the vehicle control condition for each experimental repeat. 192 
 193 
Extracellular cytokine analysis 194 
Cell supernatants were collected from culture wells for analysis of extracellular 195 
protein concentrations. Protein concentrations for IL-6, TNF-α, IL-1β and CcL-2 were 196 
measured using ‘sandwich’ based ABTS ELISA kits (PeproTech, US). In brief, 1.0 197 
µg/mL of anti-murine capture antibody was added to an ELISA microplate (NUNC 198 
maxiSorp, Fisher, UK). Following overnight incubation at room temperature, the plate 199 
was washed 4 times with wash buffer (0.05% Tween-20 PBS) before being blocked 200 
(1% BSA in PBS) for 1 hour. The plate was washed 4 times and 100 µL of serially 201 
diluted standards or supernatant sample were added and incubated at room 202 
temperature for 3 hours with moderate agitation (500 rpm). The plate was again 203 
washed 4 times before being incubated with detection antibody for 2 hours at room 204 
temperature with agitation as above. Following 4 washes, 100  µL of ABTS liquid 205 
substrate (Sigma-Aldrich, Dorset, UK) was added to each well and the plate was 206 
loaded into a Varioskan™ Flash Multimode Reader (ThermoFisher). Colour 207 
development was monitored every 10 minutes for 1 hour at 405 nm with a 208 
wavelength correction of 650 nm.   209 
 210 
Fluorescent staining 211 
Cells grown on 13 mm coverslips in 12 well plates were fixed with 3.7% 212 
formaldehyde solution made up in PBS for 30 min. Fixed cells were then washed in 213 
TBS twice and cells were permeabilised using a 0.2% Triton X-100 (Sigma) solution 214 
made up in TBS for 1 hour. Following a further two washes cells were stained with 215 
Phalloidin (1:200 in TBS) to visualise the F-actin filaments in myotubes and DAPI 216 
(1:1000) to counter stain nuclei. After an hour of incubation, cells were washed 3 x 217 
with TBS and subsequently mounted onto microscope slides with Flouromount™ 218 
aqueous mounting medium (Sigma Aldrich). Images were captured using a Leica 219 
DM2500 fluorescent microscope (Leica, UK) at 20x magnification and 7 images were 220 
obtained per coverslip, equating to 21 images per condition, per biological repeat. 221 
Analysis of myotube width and number were conducted using Image J software 222 
(NIH, Bethesda, MD). Myotubes were identified as elongated structures containing 3 223 
or more nuclei and expressing high levels of F-actin. Myotube number was counted 224 
per image and an average of 3 measures of each myotube was obtained to calculate 225 
myotube width.  226 
 227 
Assessment of tissue engineered skeletal muscle function 228 
Prior to functional tests, hydrogels were washed once in a Krebs Ringer HEPES 229 
buffer (KRH; 10mM HEPES, 138 mM NaCl, 4.7mM KCl, 1.25 mM CaCl2, 1.25 mM 230 
MgSO, 5 mM Glucose, 0.05% Bovine Serum Albumin in dH20) and attached to a 231 
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model 403A Aurora force transducer (Aurora Scientific, UK). Following the addition 232 
of 4 ml of KRH buffer, wire electrodes were positioned either side of the hydrogel in 233 
order to allow for electric field stimulation. Maximal twitch force was determined 234 
using a single 3.6 v/mm, 1.2 ms impulse and maximal tetanic force was measured 235 
using a 1 second pulse train at 100Hz and 3.6 v/mm, generated using labVIEW 2012 236 
software (National Instruments, UK). Data was acquired using Powerlab (ver. 8/35) 237 
and associated software (Labchart 8, AD Instruments, UK).  238 
 239 
Statistical Analysis 240 
Data are presented as means ± SEM unless otherwise stated (n=9). Statistical 241 
analyses were performed using SPSS v.23 (SPSS Inc., Chicago, IL, US). Data were 242 
tested for normal distribution and homogeneity of variance. A one-way analysis of 243 
variance (ANOVA), or non-parametric equivalent, for a between-between design was 244 
used to analyse the differences between conditions at a single time point. For 245 
comparisons across time points, a one-way analysis of variance (ANOVA), or non-246 
parametric equivalent, for a between-between design was used to analyse the 247 
differences between both time and condition and any interaction effect between the 248 
two. Where significance was reported, Bonferroni post-hoc tests or a series of non-249 
parametric equivalents were used to identify where any significance lay between 250 
conditions and time points. Statistical significance was assumed if p≤0.05. Further 251 
analysis of effect sizes (r) were used to calculate the magnitude of effect: Trivial 252 
<0.02; Small 0.2-0.5; Moderate 0.5-0.8; Large >0.8 (Cohen, 1992). 253 
 254 
Results   255 
LPS induces elevations in mRNA of pro-inflammatory markers in skeletal muscle 256 
myotubes 257 
To quantify the induction of pro-inflammatory markers, RT-qPCR was used to 258 
measure the mRNA expression of selected pro-inflammatory markers across a six-259 
hour time course in response to LPS exposure. A pre-defined dose of 100 ng/ml of 260 
LPS was seen to induce significant increases across all four selected markers at 261 
differing time points in comparison to CON (See Figure S1). Significant increases in 262 
TNF-α were seen at 0.5 hrs (4.97 vs. 0.97) whereas the greatest induction of IL-6 263 
(21.66 vs. 2.12) and CcL-2 (67.38 vs. 1.27) was observed at 3 hrs and IL-1β mRNA 264 
levels were significantly elevated at 6 hrs (4.00 vs. 1.98).  265 
 266 
Resolvin E1 attenuates LPS induced mRNA induction of pro-inflammatory markers 267 
and related extracellular protein release 268 
Utilising the time points optimised for maximal LPS induced mRNA expression in the 269 
initial experiments, the effects of an optimised dose of RvE1 (100 nM; See Figure S2) 270 
were investigated. Selected doses during preliminary experiments were based on 271 
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previous literature identifying RvE1 at nano-molar concentrations in-vivo (Ohira et al., 272 
2010). Cultures were simultaneously exposed to RvE1 along with LPS had reduced 273 
levels of both IL-6 (23.44 vs. 14.92, p<0.05) and CcL-2 (45.10 vs. 32.68, p<0.05) in 274 
comparison to LPS alone (Figure 1). However, no changes were noted in TNF-α 275 
(3.56 vs. 3.89, p>0.05) or IL-1β mRNA expression (2.96 vs. 2.98, p>0.05). 276 
Subsequently, extracellular protein levels of all markers were measured in the 277 
conditioned media to investigate if myokine release reflected the transcriptional 278 
changes. Twenty-four hours post LPS exposure all proteins measured showed 279 
significant increases in the LPS condition compared to that of the CON (Figure 2). 280 
However, with the addition of RvE1, significant reductions were only noted in IL-6 281 
(3900 ± 157 pg/m vs. 2500 ± 729 pg/ml, p<0.05, r=1.92). Reduced levels of both 282 
CcL-2 (20006 ± 4441 pg/m vs. 16014±4884 pg/ml, p>0.05, r=0.82) and IL-1β (11340 283 
± 3354 pg/m vs. 9223 ± 3580 pg/ml, p>0.05, r=0.59) were observed, although these 284 
changes did not reach statistical significance. No differences were noted in TNF-α 285 
extracellular protein following RvE1 addition in comparison with LPS alone (127.2 ± 286 
35.8 pg/m vs. 124.8 ± 45.4 pg/ml, p>0.05, r=0.05). 287 
 288 
RvE1 attenuates LPS induced atrophy 289 
Myotubes incubated acutely with LPS for 3 hours displayed significant atrophy at 290 
later time points, with the most severe level of morphological atrophy noted at 72 hrs 291 
post LPS exposure displaying a 53.56 % reduction compared with 24 hrs and 48 hrs 292 
(24 % and 32 % reductions, respectively: See Figure S3). When RvE1 was added to 293 
myotubes acutely along with LPS, the resulting atrophy was resolved by 31.83 % 294 
compared to the LPS condition (9.71 ± 0.59 μm vs. 15.45 ± 1.21 μm, p<0.05). No 295 
difference was seen in myotube number across all three conditions confirming the 296 
phenotypic change was atrophic in nature as opposed to being hyperplasic (Figure 297 
3).   298 
 299 
Functional resolution of LPS induced force losses in tissue engineered skeletal 300 
muscle 301 
A tissue engineering approach was adopted to investigate if LPS induced atrophy in 302 
skeletal muscle myotubes led to a decrement of its functional capacity in terms of 303 
force generation. LPS exposure was used as previously described as well as the 72 304 
hrs post exposure time point where myotube atrophy was maximal. After LPS 305 
exposure, peak tetanic force (µN) of tissue engineered skeletal muscle was 306 
significantly reduced in comparison to that of the control (93.48 ± 3.27 % vs. 59.34 ± 307 
7.07 %, p<0.05, r= 1.80). Furthermore, with the addition of RvE1 combined with LPS, 308 
force decrements were resolved by 13.35%, which although did not reach statistical 309 
significance, did represent a large effect (59.34 ± 7.07 % vs. 72.69 ± 5.15 %, p>0.05, 310 
r=1.00) (Figure 4). 311 
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 312 
Discussion 313 
The resolution of inflammation is defined as an active process and one which has 314 
been shown to be in part mediated by lipid derived SPM’s (Ohira et al., 2010). In the 315 
present investigation we sought to determine if the novel SPM, RvE1 can resolve 316 
inflammation in cultured C2C12 myotubes and thus act as a potential therapeutic for 317 
muscle wasting. This data is the first to show the pro-resolving action of RvE1 in 318 
skeletal muscle during endotoxin induced inflammation, resulting in the attenuation 319 
of muscle loss and attenuated loss of muscle function in a ‘3D’ tissue engineered 320 
skeletal muscle model. 321 
Diseases in which muscle wasting is noted are associated with elevated levels of 322 
circulating pro-inflammatory cytokines. In the present investigation, LPS (100ng) 323 
exposure resulted in elevations in mRNA levels of TNF-α, IL-6, CcL-2 and IL-1β 324 
across a 6-hour time course. These data are in agreement with Frost et al., (2002) 325 
who also found time dependent responses of these pro-inflammatory cytokines in 326 
response to a similar dose of LPS exposure in single cell myoblasts. Similar 327 
responses have also been identified  in fused myotubes further supporting the 328 
findings of the current investigation (Boyd et al., 2006). Comparable findings have 329 
also been reported utilising cytokine exposure such as TNF-α to induce IL-6 mRNA 330 
gene expression (Alvarez et al., 2002). Moreover, in the present study conditioned 331 
medium samples from myotube cultures 24 hours after an acute 3 hour LPS 332 
exposure showed elevations in myokine levels of IL-6, TNF-α, IL-1β and CcL-2 333 
which also mirrors responses previously reported in the in-vitro literature (McCoin et 334 
al., 2015; Podbregar et al., 2013; Peake et al., 2015) as well as displaying similar 335 
trends to in-vivo investigations (Lang et al., 2003). Therefore, exposure of C2C12 336 
myotubes to 100ng LPS over a 3-hour time course provided an ideal model to 337 
explore the effect of RvE1. 338 
Addition of RvE1 to the culture medium alongside LPS resulted in substantial 339 
attenuation of the mRNA induction of pro-inflammatory cytokines, and whilst these 340 
were not directly mirrored in the secreted extracellular levels of corresponding 341 
proteins, there was clear evidence of attenuated levels. Similar trend reductions 342 
have been seen in CcL-2 in regards to the effects of RvE1 (Lund et al., 2010), though 343 
the current work showed contradictory effects on TNF-α. This suggests that RvE1 has 344 
tissue-specific effects however dampening of LPS induced myotube inflammation in 345 
our model highlights the efficacy of the use of RvE1 in this cell type/tissue indicating 346 
that it may be an important nutritional therapeutic for reducing inflammation in 347 
skeletal muscle. 348 
Elevations in pro-inflammatory cytokines have previously been shown to induce an 349 
atrophic response in muscle cells in vitro (Magee, Pearson & Allen 2008; Romanick, 350 
Thompson & Brown-Borg, 2013) suggesting that the inflammation observed in 351 
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human diseases may be a major driver of the associated muscle wasting. In the 352 
present study, 3 hours of incubation with LPS resulted in 46% myotube atrophy 72 353 
hours later, similar to that observed by both Yi-Ping et al, (2000) and Magee et al., 354 
(2016) in response to TNF-α exposure. However, when LPS was co-incubated with 355 
RvE1 myotube size was preserved, with only a small (~14%) reduction compared to 356 
control cells. Interestingly, the current data set suggests that the attenuation of an 357 
atrophic phenotype utilising RvE1 is via an attenuation of IL-6 with no effect seen on 358 
TNF-α. This is contradictory to previous research identifying TNF-α as a key 359 
mediator of cachexia, thus future research should look to investigate these signalling 360 
differences across tissue type and based upon specific interventions.  Furthermore, 361 
this ~14% reduction equated to a greater preservation of myotube size than that 362 
seen in response to EPA incubation in a pro-inflammatory state (Magee, Pearson & 363 
Allen 2008). Though the time course and inflammatory stimulus differed to the 364 
current investigation, our data provides initial evidence that RvE1 may have greater 365 
pro-resolving properties in skeletal muscle.  366 
Tissue engineered muscle models have been shown to closely replicate the 367 
physiology and function of native tissue, with more recent studies utilising them to 368 
closely replicate muscle from diseases with associated changes in muscle 369 
phenotype (Martin et al., 2017; Martin et al., 2017). Further to this, work in tissue 370 
engineered constructs has defined the linear relationship between myotube 371 
phenotype in tissue engineered constructs and force output (Martin et al., 2013), as 372 
well as its ability to produce classic muscle mechanics closely replicative of native 373 
tissue (Huang et al., 2005). Thus, the use of this model as an assay of force 374 
production allowed us to contextualise our molecular and morphological findings, 375 
depicting that RvE1 prevents decrements in maximal force production associated with 376 
LPS exposure. This data suggests that RvE1 associated attenuation of inflammation 377 
is capable of having positive effects on muscle phenotype (size and function).  378 
The proposed mechanism of action by which RvE1 impacts the inflammatory 379 
resolution process has been shown to differ between cell types. Two cell surface 380 
receptors have been identified for RvE1; Leukotriene B4 receptor 1 (BLTR1) and the 381 
G-protein coupled receptor  Chemerin Receptor 23 (ChemR23) (Arita et al., 2007; 382 
Norling & Perretti, 2013; Cash, Norling & Perretti, 2014); the latter of which has 383 
previously been reported to be expressed on the sarcolemma of skeletal muscle 384 
(Sell et al., 2009). RvE1 has been shown to display specific binding to ChemR23 with 385 
a Kd of 11.3 nM, resulting in the attenuation of TNF-α mediated NFκB activation (Arita 386 
et al., 2005; Ohira et al., 2010). With the current findings providing the initial 387 
evidence for the pro-resolving capacity of RvE1 in skeletal muscle, future work needs 388 
to seek to understand whether beneficial effects of RvE1 are receptor dependent, and 389 
if so, provide an insight into the identity to direct future investigations for therapeutic 390 
strategies in cachexic disease states. 391 
In conclusion, the current work has systematically developed an in-vitro method of 392 
LPS induced inflammatory atrophy in skeletal muscle myotubes for the screening of 393 
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anti-Inflammatory/pro-resolving compounds. The process used both mono-layer in-394 
vitro approaches as well as recently defined ‘3D’ tissue engineered skeletal muscle 395 
culture, to enable the quantification of the effect of inflammatory atrophy on 396 
functional output in a controlled culture setting. Using these methodologies, we have 397 
shown potential application of RvE1 in this cell type. Future work should be directed 398 
towards investigating the specific binding potential of RvE1 in skeletal muscle, to 399 
identify its mechanism of action, furthering our understanding of its potential role as a 400 
naturally occurring pro-resolving mediator in diseases states with associated 401 
cachexia as well as in ageing populations. 402 
 403 
 404 
 405 
  406 
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Figure 2: Pro-inflammatory cytokine extracellular protein concentrations in response 618 
to 100 ng/ml LPS or LPS + RvE1 100 nM in comparison with an unstimulated control 619 
(CON) 24h post stimulation. RvE1 attenuated the elevation in IL-6 in the cell culture 620 
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medium following LPS stimulation, whilst having little effect on TNF-α, CcL-2 and IL-621 
1β. Data displayed as mean ± SEM, * denoting p<0.05 between the condition and 622 
CON. # denoting p<0.05 between LPS and LPS+ RvE1. 623 
Figure 3: Myotube morphology 72 hrs following acute (3 hrs) exposure to 100 ng/ml 624 
LPS. The presence of LPS alone or in combination with RvE1 has no effect on 625 
myotube number (a). In comparison, myotube atrophy occurs (b) following LPS 626 
exposure which is prevented by co-incubation with RvE1. Data are expressed as 627 
mean ± SEM. * denoting p<0.05 between the condition and CON. # denoting p<0.05 628 
between LPS and LPS+RvE1.  629 
Figure 4: Maximal contractile force from engineered muscles cultured for 72 hrs 630 
following acute (3 hrs) incubation with 100 ng/ml LPS or LPS + RvE1 100 nM. 631 
Incubation of engineered muscle with LPS resulted in impaired muscle function 632 
which was partially prevented by co-incubation with RvE1. All conditions were 633 
compared to CON controls within individual experiments to calculate relative force. 634 
Data are expressed as mean ± SEM * denoting p<0.05 between the condition and 635 
CON. 636 
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